

Complete if Known Substitute for form 1449A/PTO 10/686,619 Application Number INFORMATION DISCLOSURE October 17, 2003 Filing Date STATEMENT BY APPLICANT Margot Mary O'TOOLE et al. First Named Inventor (use as many sheets as necessary) 1614 Art Unit Theresa Frederick Examiner Name Sheet 1 of 4 Attorney Docket Number 031896-004000 (AM100990)

			U.S. PATENT DO	CUMENTS	
Examiner Initials	Cite No.	U.S. Patent Document Number - Kind Code ² (if beown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KS	 	US-6280941	08/28/2001	Tsao et al.	
		US-4690905	09/01/1987	Diamond et al.	
	1	US-5919619	07/06/1999	Tullis	
		US-6506559	01/14/2003	Fire et al.	
		US-4935233	06/19/1990	Bell et al.	
		US-4751180	06/14/1988	Cousens et al.	
		US-4980281	12/25/1990	Housey	
		US-5266464	11/30/1993	Housey	
		US-5688635	11/18/1997	Parker et al.	
		US-5877007	03/02/1999	Housey	
	1	US-4671958	06/09/1987	Rodwell et al.	
	1	US-4489710	12/25/1984	Spitler	
	1	US-4625014	11/25/1986	Senter et al.	
		US-4638045	01/20/1987	Kohn et al.	
		US-4671958	06/09/1987	Rodwell et al	
	 	US-4569789	02/11/1986	Blattler et al.	
		US-5498531	03/12/1996	Jarrell	
1/		US-5459039	10/17/1995	Modrich et al.	
V	1	US-4522811	06/11/1985	Eppstein et al.	

		FC	REIGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Kind Code ³ Country Code ³ Number ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ•
KS		WO-99/14346	03/25/1999	Woolf		
		WO-01/70949	09/27/2001	Graham et al.		
		WO-01/36646	05/25/2001	Zemicka-Goetz et al		
		WO-00/63364	10/26/2000	Pachuk et al.		
		WO-00/44895	08/03/2000	Kreutzer et al		
		WO-01/75164	10/11/2001	Tuschl et al.		
		WO-01/92513	12/06/2001	Arndt et al.		
		WO-01/68836	09/20/2001	Beach et al.		
1		WO-01/29058	04/26/2001	Mello et al.		
		WO-97/07668	03/06/1997	Campbell et al.		
$\overline{\mathbf{M}}$		WO-97/07669	03/06/1997	Campbell et al.		
		WO-89/10134	11/02/1989	Pardridge et al.		
Evaminer				Date	·	

	WO-09/10134	11/02/1909	r aruriuge et ai.	
Examiner	/75 - 4-1	J /	Date	
Signature	/Katherine Sa	almon/	Considered	08/24/2006

[•]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

<u></u>	hstitut	e for form	1449B'PTO		 :-		Complete if Known	
						Andiestica Number	10/686,619	
I	NFO	RMA	TION I	DISC	LOSURE	Application Number	October 17, 200)3
S	TAT	TEME	ENT BY	APP	LICANT	Filing Date	Margot Mary O	
		(use as	many sheets o	аз песем	(جره	First Named Inventor	1614	TOOLD GLUI
						Group Art Unit	Theresa Frederi	ck
<u> </u>		2		Of	14	Examiner Name		
Sh	ec:	-		<u> </u>	<u> </u>	Attorney Docket Number	031896-004000	(100990)
_		Cite	T			RT - NON PATENT LITERAT	of the article (when appropriate), title of the	
Exam Initial		No.1		item (b	ook, magazine, joun	nal, serial, symposium, catalog, et publisher, city and/or country wi	c.)., date, page(s), volume-issue number(s), here published.	
K	S				OULUS, A. N Today 15:150-:		nunity: Part Ii. Genetic Predis _i	position,
			SUN et	al., <i>J</i> .	Neuropathol I	Exp Neurol, 56:1339-13	48, 1997	
$\vdash \vdash$		 	KADO	N/ A TC	Siletal Pr I	Cancer, 75:354-359, 19	97	
			, KADO.	MAIS	50 ct al., <i>bi</i> 5 t	Cancer, 13.334-339, 19	71	
			CHOU	DHUR	I et al., Cance	r Res., 75:354-359, 199	7	
			TAKEI	et al.,	Cancer Res.,	61:8486-8491, 2001		
			TAKEI	et al.,	J. Biol Chem	Embo J, 16:6936-6946	, 1997	
			INUI, 7	ratsu	JYA, et al., Pe	ptide Institute Inc., J Pe	pt Sci 2:28-39, 1996	
			MURA	MATS	SU et al., <i>Bioci</i>	hem Biophys Res Comm	un 203:1131-1139, 1994	
			ASAI e	t al., <i>B</i>	Biochem Bioph	ys Res Commun, 203:11	131-1139, 1994	
			KANEI	DA et	al., <i>Biochem B</i>	iophys Res Commun, 22	20:108-112, 1996	
			PEDRA	ZA et	al., J Biochen	ı, 117: 845-849, 1995		
			AHME	D et al	., Cancer Lett,	, 180: 159-63, 2002		
			AHME	D et al	., Int. J. Mol. I	Med., 6:281-287, 2000		
			URIOS	et al.,	Biochem Biop	ohys Res Commun 175:	617-627, 1991	
1	/		NAIR e	t al., /	Veuroscience, S	85:759-771, 1998		

Complete if Known Substitute for form 1449A/PTO 10/686,619 Application Number INFORMATION DISCLOSURE October 17, 2003 Filing Date STATEMENT BY APPLICANT Margot Mary O'TOOLE et al. First Named Inventor (use as many sheets as necessary) 1614 An Unit Theresa Frederick Examiner Name Attorney Docket Number 3 Of 4 031896-004000 (AM100990) Sheet

		SUI et al., Proc. Nat'l. Acad. Sci. USA, 99: 5515-5520, 2002	_
KS			
1		LEE et al., Nature Biotechnology, 20:500-505, 2002	
		NEEDLEMAN and WUNSCH, J. Mol. Biol., 48:444-453, 1970	
			<u> </u>
		ALTSCHUL et al., Polynucleotides Res 25 (17): 3389-3402, (1997).	
		MARATEA et al., Gene, 40:39-46, 1985	
			ļ
		MURPHY et al., Proc. Nat'l Acad. Sci. USA, 83:8258-8262, 1986	
		DELGRAVE et al., Protein Engineering, 6: 327-331, 1993	
	<u> </u>	200000	
		GOSSEN et al., Science, 268: 1766-1769, 1995	
_		NO et al., Proc. Nat'l. Acad. Sci. USA, 93: 3346-3351, 1996	
		NO et al., Froc. Nat 1. Acad. Sci. USA, 93. 3340-3331, 1220	
	-	WANG et al., Nat. Biotech, 15: 239-243, 1997	
_		YE et al., Science 283: 88-91, 1999	
<u> </u>	 	ZUCKERMANN et al. 1994, J. Med. Chem. 37:2678-85	
_	<u> </u>	LAM, Anticancer Drug Des., 12: 145, 1997	
		GUATELLI et al., Proc. Natl. Acad. Sci. USA, 87: 1874-1878, 1990	
		KWOH et al., Proc. Natl. Acad. Sci. USA, 86: 1173-1177, 1989	
			<u> </u>
1/		LIZARDI et al. Q-Beta Replicase, Bio-Technology 6: 1197, 1988	
V			

Substitute for form 1449A/PTO		Complete if Known					
INFORMATION DISCLOSURE		Application Number	10/686,619				
		Filing Date	October 17, 2003				
STAT	STATEMENT BY APPLICANT (use as many sheets as necessary)		First Named Inventor	Margot Mary O'TOOLE et			
			Art Unit	1614			
	05 4				Examiner Name	Theresa Frederick	
Sheet	4	(of	4	Attorney Docket Number	031896-004000 (AM10099	
KS		MYERS et al., Science, 230: 1242, 1985					
		KEEN et	al., 7	rends Genet,	7:5, 1991		
-		ROSENB	BAUN	A and REISS	NER, Biophys Chem 265: 12	2753, 1987	
		SAIKI et	al., <i>F</i>	Proc. Natl. Ac	ad. Sci USA, 86:6230, 1989		
		O'GORM	1AN	et al., <i>Science</i>	, 251:1351-1355, 1991		
		WILMUT	Γ, Ι. ϵ	et al., <i>Nature</i> 3	85:810-813, 1997		
+		LOCKHA	ART	et al., Nature	Biotechnology, 14, 1675-80), 1996	
+	-	HILL et a	al., <i>G</i>	enome Biol. 2	Res, 0055.1-0055.13, 200	1	

Examiner	/Katherine Salmon/	Date Considered	08/24/2006

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

OIPE	1098
图 服 23	ME SELOT
Vin	.037

2

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

C	Complete if Known				
Application Number	10/686,619				
Filing Date	October 17, 2003				
First Named Inventor	Margot Mary O'TOOLE et al.				
Art Unit	- 1614				
Examiner Name	Theresa Frederick				
Attorney Docket Number	031896-004000 (AM100990)				

Γ	U.S. PATENT DOCUMENTS						
	Examiner Initials	Cite No. [†]	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columna, Lines, Where Relevant Passages or Relevant Figures Appear	
ſ							

		FC	REIGN PATENT I	OCUMENTS		
Examiner Initials	Cite No. ¹	Foreign Patent Document Kind Code ³ Country Code ³ Number ⁴ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7*
·KS		EP 1 215 500 A	06-19-2002	Muramatsu		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
KS		MISHIMA, et al., "Increased expression of midkine during the progression of human astrocytomas", Neuroscience Letters, Vol., 233, No. 1, pages 29-32, (1997)	
		TSUTSUI, et al., "A new family of heparin-binding growth/differentiation factors: Increased midkine expression in Wilms' tumor and other human carcinomas", Cancer Research, Vol. 53, No. 6, pages 1281-1285, (1993)	
		KUROSAWA, et al., "Midkine binds specifically to sulfatide. The role of sulfatide in cell attachment to midkine-coated surfaces", European Journal of Biochemistry, Vol. 267, No. 2, January 2000	
		ZOU, et al., "A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican", European Journal of Biochemistry, Vol. 267, No. 13, July 2000	
		SAID, et al., "The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor", <i>Journal of Biological Chemistry</i> , Vol. 277, No. 40, pages 37492October 4, 2002	
		STOICA, et al., "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types", <i>Journal of Biological Chemistry</i> , Vol. 277, No. 39, pages 35990-35998, September 27, 2002	
\downarrow		IKEDA, et al., "Effects of midkine during in vitro maturation of bovine oocytes on subsequent developmental competence", <i>Biology of Reproduction</i> , Vol. 63, No. 4, pages 1067-1074, October 2000	

FEB 2 3 2005 W

Substitute for form 1449A/PTO RADEMAN	
INFORMATION DISCLOSURE	C
STATEMENT BY APPLICANT	•

(use as many sheets as necessary)

of

Complete if Known					
Application Number	10/686,619				
Filing Date	October 17, 2003				
First Named Inventor	Margot Mary O'TOOLE et al.				
Art Unit	1614				
Examiner Name	Theresa Frederick				
Attorney Docket Number	031896-004000 (AM100990)				

			U.S. PATENT DOC	UMENTS			
Examiner Initials	Cite No.'	U.S. Patent Document Number - Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Wh Passages or Relevant Figu		
			FOREIGN PATENT D	OCUMENTS			
Examiner Initials*	Cite No. ¹	Foreign Patent Document Kind Cod Country Code ³ Number ⁴ (if know		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	. T°	
		1					
		OTHER PRIC	DR ART – NON PATENT I	ITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.					
ĶS				n in intrahepatic cholangioca ion analyses", <i>Liver</i> , Vol. 20			
KS		Midkine MK Sequences	Between the Huma	n-Binding Factors Strong Con and the Mouse", <i>Biochemia</i> . 176, No. 2, pages 792-797,	cal and		
•			·				
				<u> </u>			

Examiner	/Katherine Salmon/	Date	09/05/2006
Signature	/ Muchot the Duthon/	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222 uspto gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OIPE CO. S.
TRADES

<u> </u>	<u>7</u>								
& TRADEN	for form 14	49A/PTO				Complete	if Know	7	
INFO	DMAT	ION DISC	T OSTIE	F	Application N	umber	10/686,619		
					Filing Date		Octob	er 17, 2003	
21A1	TATEMENT BY APPLICANT (use as many sheets as necessary)				First Named In	nventor	Margo	t Mary O'TOOLE	et al.
	(use as m	any sheets as necess	ary)		Art Unit		1614		
					Examiner Nam	ne	Theres	sa Frederick	
Sheet	1	of	1		Attorney Dock	cet Number	03189	6-004000 (AM1009	990)
				U	J.S. PATENT DOC	UMENTS			
Examiner	Cite	U.S. Patent Do	cument		Publication Date	Name of Patentee o	_ •	Pages, Columns, Lines, When	re Relevant
Initials*	No.¹	Number - Kind Code	ode ² (if known)		MM-DD-YYYY	Applicant of Cited Document		Passages or Relevant Figures Appear	
								_	
_				FOR	REIGN PATENT D	OCUMENTS			
Examiner Initials	Cite No. ¹	Foreign Pat	tent Document Kind (mber ⁴ (if kn	Code ³	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Docu		rages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
			OTHER PRI	OR AR	RT – NON PATENT L	ITERATURE DOCUMEN	(TS		
Examiner Initials	Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.						
KS		International	Applicat	ion N	lo. PCT/US2003	/33054, Internationa	al Search	Report mailed	

Examine Initials		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.			
K	KS		International Application No. PCT/US2003/33054, International Search Report mailed August 3, 2004, 3 pages			
			ASAI, T. et al., "Identification of heparin-binding sites in midkine and their role in neurite-promotion," Biochem. Biophys. Res. Commun., 236(1):66-70 (1997)			
			IWASAKI, W. et al., "Solution structure of midkine, a new heparin-binding growth factor," EMBO J., 16(23):6936-6946 (1997)			
	MYERS, E.W. and MILLER, W., Optical alignments in linea (1988)		MYERS, E.W. and MILLER, W., Optical alignments in linear space, CABIOS, 4(1):11-17 (1988)			
			MURAMATSU, H. et al., "Localization of heparin-binding, neurite outgrowth and antigenic regions of midkine molecule," Biochem. Biophys. Res. Commun., 203(2):1131-1139 (1994)			
	/		TAKEI, Y. et al., "5'-,3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine, its design and application for cancer therapy," J. Biol. Chem., 277(26):23800-23806 (2002)			

_			
Examiner		Date .	
Signature	/Katherine_Salmon/	Considered	08/24/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



	TOPE	ON THANKS		· · · · · · · · · · · · · · · · · · ·					
Substitute	for form 1	449A/PTO			Ca	mplete ij			
INFO	RMA'	TION DISCLOS	URE	Application	Number		10/686,6		
STAT	'EME	NT BY APPLIC	ANT	Filing Date			October		
(use as many sheets as necessary)		First Named	Inventor			Mary O'TOOLE	et al.		
				Art Unit			1634		
				Examiner N				Shin Shin Wong	
Sheet	1	of 2		Attorney Do	cket Number		031896-	004000 (AM100	1990)
			i	J.S. PATENT DO	CUMENTS		· 		
Examiner	Cite No.	U.S. Patent Docume	រាវ	Publication Date	Name	e of Patentee or		Pages, Columns, Lin	es, Where
Initials*	NO.	Number - Kind Code ² (if know	ข	MM-DD-YYYY		of Cited Docum		Relevant Passages or Figures Appe	
KS		U.S. – 4,554,101		11-19-1985	HOPP, T.				
KS		U.S 2003/01482	98 A 1	08-07-2003	O'TOOLE	, M. et al	<u> </u>		
Examiner Signature					Date Considered				
			FOF	REIGN PATENT	DOCUMENTS				
Examiner Initials	Cite No. ¹		nt nd Code ³	Publication Date MM-DD-YYYY	Name of Pa Applicant of Cit			Columns, Lines, Where ant Passages or Relevant Figures Appear	т*
KS		WO 2004/036221		04-29-2004	O'TOOLE et	t al.			
Examiner Signature					Date Considered				
Jigilataic		OTHER PR	IOR ART	-NON PATEN		: DOCUMI	ENTS		
Examiner Initials	Cite No. ¹	Include name o item (book, ma	f the author gazine, journ	(in CAPITAL LETT nal, serial, symposium publisher, city and/o	ERS), title of the arm, catalog, etc.)., date or country where pul	ticle (when ap le, page(s), vo blished.	ppropriate), t blume-issue n	iumber(s),	T ²
KS		FRAMPTON, G. et systemic lupus erytl protein P0 as an end 2000	nematosi	us using a mole	cular cloning	strategy:	a role for	r ribosomal P	
		ADACHI, M., et al							
		DUAN, J. et al., Pro and site-directed mu	posed li	pocalin fold fo	r apolipoprote	in M bas	ed on bio		
	HAMMOND, C. et al., The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules, J. Immunol., 161(7):3282-3291, 1998								
	HECKENLIVELY, J. R. et al., Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration, Arch. Ophthalmol., 118(2):1525-1533, 2000								
		LAGAUDRIERE-C both free HLA class Immunol., 158(6):2	I heavy	chain and hete	e tetraspanin j erodimeric bet	protein C a 2-micro	D82 asso	ciates with complexes, J.	
		LEBEL-BINAY, S. is a costimulatory p	rotein fo	r T cell activat	ion, <i>J. Immun</i>	ol., 155(1):101-11	0, 1995	
$ \Psi $		MAEDA, A. et al., induces autoimmun Immunol., 32:2300-	e retinal	dysfunction ar	erin, a cancer ad tumor cell r	-associate egression	ed retinop in mice,	eathy antigen, .Eur. J.	<u> </u>
Examiner Signature		/Katherin	e Sal	mon/	Date Considered		09/0	5/2006	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitu	ne for form 1449	A/PTO		Complete if Known		
INEC	DRMATI	ON DISC	LOSURE	Application Number	10/686,619	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	October 17, 2003	
(use as many sheets as necessary)		First Named Inventor	Margot Mary O'TOOLE et al.			
	(100 10 1101)	,	-,,	Art Unit	1634	
		Examiner Name	Jennifer Shin Shin Wong			
Sheet	2	of	2	Attorney Docket Number	031896-004000 (AM100990)	

	Circ	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T ²				
Examiner Cite No. 1		item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.					
KS		ROTH, W. et al., Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells, Oncogene, 19(37):4210-4220, 2000					
		XU, N. et al., Effects of platelet-activating factor, tumor necrosis factor, and interleukin- lalpha on the expression of apolipoprotein M in HepG2 cells, Biochem. Biophys. Res. Commun., 292(4):944-950, 2002					
		XU, N. et al., A novel human apolipoprotein (apoM), J. Biol. Chem., 274(44):31286-31290, 1999					
		YOSHINO, K. et al., Secreted Frizzled-related proteins can regulate metanephric development, Mech. Dev., 102(1-2):45-55, 2001					
		LEE, N. S. et al., Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells, Nat. Biotechnol., 20(5):500-505, 2002					
		BAZHIN, A. V. et al., Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer but without a loss of vision, Lung Cancer, 34(1):99-104, 2001					
		International Search Report for International Application No. PCT/US2004/005655, mailed November 8, 2004, 6 sheets					
		ROZZO, S. J. et al., Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus, <i>Immunity</i> , 15(3): 435-443, 2001					
		MOSER, K. L. et al., The use of microarrays to study autoimmunity, J. Investig. Dermatol. Symp. Proc., 9(1):18-22, 2004					
V		BENNETT, L. et al., Interferon and granulopoiesis signatures in systemic lupus erythematosus blood, J. Exp. Med., 97(6):711-723, 2003					

Examiner	/7-+11 0-1/	Date	09/05/2006
Signature	/Katherine Salmon/	Considered	03/03/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.